By James Riddle, VP of Institutional Services
COVID-19 is rapidly changing the way research is conducted. One of the biggest changes is the move from traditional face-to-face interactions toward remote visits, remote data collection, and other virtual trial approaches. It is critical for IRBs to understand how these technologies work, their risks, and how risks are communicated to participants. Virtual trial technology usage will increase as we accelerate the recovery, but the regulations governing IRB criteria for approval of research and the underlying ethical considerations have not changed.